Mencord Plus (Olmesartan Medoxomil, Hydrochlorothiazide)

Mencord Plus, a combination antihypertensive, acts on the renin‑angiotensin system and promotes diuresis to control elevated blood pressure.

• Hypertension: reduces systolic and diastolic blood pressure in patients with primary hypertension, aiding long‑term cardiovascular risk management.

• Olmesartan medoxomil selectively blocks angiotensin II type 1 (AT1) receptors, preventing vasoconstriction and aldosterone release, while hydrochlorothiazide inhibits Na⁺/Cl⁻ reabsorption in the distal convoluted tubule, increasing urinary sodium and water excretion. The combined actions lower peripheral vascular resistance and plasma volume, resulting in reduced arterial pressure.

Mencord Plus may cause a range of adverse reactions. Patients should be aware of both frequent and rare events.

Common Side Effects

• Dizziness: transient light‑headedness, especially after the first doses.
• Headache: mild to moderate intensity, often resolves with continued therapy.
• Increased urination: due to the diuretic component, leading to more frequent bathroom visits.
• Electrolyte imbalance: mild reductions in potassium or sodium levels.
• Fatigue: general feeling of tiredness during early treatment.

Serious or Rare Side Effects

• Severe allergic reaction: rash, swelling, or difficulty breathing requiring immediate medical attention.
• Acute kidney injury: sudden decline in renal function, particularly in patients with pre‑existing kidney disease.
• Hyperkalemia: elevated blood potassium that can cause cardiac arrhythmias.
• Severe hypotension: marked drop in blood pressure leading to fainting or shock.
• Pancreatitis: rare inflammation of the pancreas presenting with abdominal pain and vomiting.

Before prescribing Mencord Plus, clinicians should consider several safety aspects.

• Renal function monitoring: assess serum creatinine and eGFR periodically.
• Electrolyte surveillance: check potassium and sodium levels, especially in patients on other diuretics.
• Caution in the elderly: start at lower doses to reduce risk of orthostatic hypotension.
• Avoid in severe hepatic impairment: drug metabolism may be altered.
• Pregnancy and lactation: safety not established; use only if potential benefit outweighs risk.
• Store at room temperature: keep in the original container, protect from moisture and light.

Mencord Plus can interact with several medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid)

• Aliskiren in diabetic patients: combined use may increase renal risk.
• ACE inhibitors or other ARBs: may cause excessive potassium rise and renal dysfunction.
• Lithium: risk of lithium toxicity due to reduced clearance.
• NSAIDs: may blunt antihypertensive effect and impair renal function.
• Other potassium‑sparing diuretics: increase risk of hyperkalemia.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: additive blood‑pressure lowering effect; monitor for hypotension.
• Calcium channel blockers: may enhance antihypertensive response.
• Warfarin: possible alteration of INR; check coagulation status.
• Antidiabetic agents: diuretic may affect glucose control; monitor blood sugar.
• Antimicrobials (e.g., ciprofloxacin): may increase serum levels of olmesartan.